| This week's sponsor is FierceBiotech. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. Publisher's Note: FierceLifeSci Weekly Digest won't be in your inbox next week, but we will be covering breaking news on FiercePharma.com nad FierceBiotech.com. Our newsletters will be back in the New Year. Happy holidays! | |
|
Featured Story | | | Friday, December 14, 2018 Bellicum Pharma has the first data on BPX-601, its first CAR-T with a built-in activation switch to boost its effects, and says initial results show signs of biologic activity. |
|
|
Top Stories Of The Week Monday, December 17, 2018 AbbVie has been on a hot streak lately thanks to the performance of its bestselling Humira, but as the company looks to the future, it has decided to tweak its management team. The company is consolidating its executive team into four managers who will report to CEO Richard Gonzalez. Friday, December 14, 2018 Axovant has licensed two gene therapies from the University of Massachusetts Medical School. The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic. Tuesday, December 18, 2018 Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses from meeting specifications, a problem that is also hampering Kymriah sales. Wednesday, December 19, 2018 General Electric has submitted a confidential filing to spin out its healthcare business into a publicly traded company, with an IPO likely taking place early next year, according to reports. Friday, December 14, 2018 Teva has already decided to move its U.S. headquarters, and now it’s planning to move its worldwide headquarters, too. The company will relocate to Tel Aviv from Petah Tikvah, Israel, in mid-2020. Monday, December 17, 2018 Some neurons never get clogged up with tau, the toxic protein that's been implicated in Alzheimer's and other neurodegenerative disorders. A team of scientists led by the Columbia University Vagelos College of Physicians has discovered why—and the finding could lead to new ideas for treating the disease. Monday, December 17, 2018 Johnson & Johnson is taking its baby powder case to consumers. A new print and online ad will begin running this week contending “Our talc is safe” and asking people to read the scientific evidence for themselves. Friday, December 21, 2018 Among our most-read headlines of 2018, you’ll notice industry themes that either dominated the news all year or simply returned as they have again and again in the tune biopharma has written for itself over the decades. And, of course, the scandals. Friday, December 21, 2018 As we near the end of the year, we like to take a look back over the biggest stories of 2018 and gauge what you, dear reader, found the most interesting, rewarding or controversial. This year, controversy and so-called negative news took precedent, although our biggest story by a large margin centered around Bill Gates and a new startup. Friday, December 21, 2018 The sad, strange Theranos saga has typically made strong showings on our past annual lists of FierceMedtech’s most-read stories—but this year, barring the unforeseeable, will be its last, as the company finally bled dry this September and announced plans for liquidation. Resources Sponsored by: DocuSign Life sciences companies must immediately identify and realize productivity gains to drive down operational costs—or risk seeing more nimble competitors disappear into the distance. Where to begin? Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 